Literature DB >> 27566027

Prognostic factors and adjuvant therapy on survival in early-stage cervical adenocarcinoma/adenosquamous carcinoma after primary radical surgery: A Taiwanese Gynecologic Oncology Group (TGOG) study.

Nae-Fang Twu1, Yu-Che Ou2, Cheng-I Liao3, Wei-Yang Chang4, Lan-Yan Yang5, Yun-Hsin Tang6, Tze-Chien Chen7, Chi-Hau Chen8, Tze-Ho Chen9, Lain-Shung Yeh10, Shih-Tien Hsu11, Yu-Chieh Chen12, Cheng-Chang Chang13, Ya-Min Cheng14, Chia-Yen Huang15, Fu-Shing Liu16, Yue-Shan Lin17, Sheng-Mou Hsiao18, Yuan-Yee Kan19, Chyong-Huey Lai20.   

Abstract

OBJECTIVE: We aimed to identify prognostic factors of early-stage cervical adenocarcinoma (AC) and adenosquamous carcinoma (ASC) treated with primary radical surgery, and to evaluate the impact of postoperative adjuvant therapy on outcome.
METHODS: The clinical-pathological data of all patients (n = 1132) with stages I-II cervical AC/ASC treated with primary radical surgery at the member hospitals of the Taiwanese Gynecologic Oncology Group were retrospectively reviewed.
RESULTS: In multivariate analysis, stage II, deep stromal invasion (DSI), lymphovascular space invasion (LVSI), positive pelvic lymph node (PLN), and parametrial involvement (PI) were significant factors for recurrence-free survival (RFS), while only DSI, PI, and positive PLN were independent factors for cancer-specific survival (CSS). Low- and high-risk groups were defined by prognostic scores derived from the four factors (DSI, LVSI, positive PLN, PI) selected by internal validation. Postoperative adjuvant therapy significantly improved outcome for PLN-positive patients (RFS, p = 0.014; CSS, p = 0.016), but not for PLN-negative high-risk group because of higher mean prognostic score (p = 0.028) of adjuvant+ than adjuvant- patients.
CONCLUSIONS: PLN metastasis, PI, DSI, and LVSI were independent prognostic factors. Prospective studies of postoperative adjuvant therapy with prognostic score and nodal status stratification for cervical AC/ASC are necessary.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Adenocarcinoma; Adenosquamous carcinoma; Adjuvant therapy; Cervical cancer; Prognostic factor

Mesh:

Year:  2016        PMID: 27566027     DOI: 10.1016/j.suronc.2016.05.028

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  10 in total

1.  Prognostic evaluation of postoperative adjuvant therapy for operable cervical cancer: 10 years' experience of National Cancer Center in China.

Authors:  Tong Shu; Dan Zhao; Bin Li; Yating Wang; Shuanghuan Liu; Pingping Li; Jing Zuo; Ping Bai; Rong Zhang; Lingying Wu
Journal:  Chin J Cancer Res       Date:  2017-12       Impact factor: 5.087

Review 2.  Short-term recurrence and distant metastasis following robotic-assisted radical hysterectomy with pelvic lymphadenectomy and chemoradiotherapy for a stage IB1 cervical adenocarcinoma: A case report and literature review.

Authors:  Jinfei Tong; Hailan Yu; Jianqiong Li; Jiena Zhou; Xudong Ma; Jianhua Yang
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

3.  MRI Radiomic Features: A Potential Biomarker for Progression-Free Survival Prediction of Patients With Locally Advanced Cervical Cancer Undergoing Surgery.

Authors:  Mengting Cai; Fei Yao; Jie Ding; Ruru Zheng; Xiaowan Huang; Yunjun Yang; Feng Lin; Zhangyong Hu
Journal:  Front Oncol       Date:  2021-12-14       Impact factor: 6.244

4.  Risk Factor Assessment of Lymph Node Metastasis in Patients With FIGO Stage IB1 Cervical Cancer.

Authors:  Mu Xu; Xiaoyan Xie; Liangzhi Cai; Yongjin Xie; Qiao Gao; Pengming Sun
Journal:  Front Oncol       Date:  2022-03-30       Impact factor: 6.244

5.  The best postoperative adjuvant therapy for patients with early stage cervical adenosquamous carcinoma.

Authors:  Yawen Liu; Haiyan Tu; Lingling Zhang; Meiling Zhong; Yanan Wang; Ling Li; Xiaojun Xiang
Journal:  BMC Womens Health       Date:  2022-04-12       Impact factor: 2.809

6.  Cervical cancer prognosis and related risk factors for patients with cervical cancer: a long-term retrospective cohort study.

Authors:  Jina Li; Gaoming Liu; Jiayou Luo; Shipeng Yan; Ping Ye; Jie Wang; Miyang Luo
Journal:  Sci Rep       Date:  2022-08-17       Impact factor: 4.996

7.  Comparison of adenocarcinoma and adenosquamous carcinoma prognoses in Chinese patients with FIGO stage IB-IIA cervical cancer following radical surgery.

Authors:  Xiaojing Zhang; Zunfu Lv; Xiaoxian Xu; Zhuomin Yin; Hanmei Lou
Journal:  BMC Cancer       Date:  2020-07-16       Impact factor: 4.430

8.  Tumor Size at Magnetic Resonance Imaging Association With Lymph Node Metastasis and Lymphovascular Space Invasion in Resectable Cervical Cancer: A Multicenter Evaluation of Surgical Specimens.

Authors:  Xiao-Li Chen; Guang-Wen Chen; Guo-Hui Xu; Jing Ren; Zhen-Lin Li; Hong Pu; Hang Li
Journal:  Int J Gynecol Cancer       Date:  2018-10       Impact factor: 3.437

9.  The clinical and prognostic implication of deep stromal invasion in cervical cancer patients undergoing radical hysterectomy.

Authors:  Jun Zhu; Lijie Cao; Hao Wen; Rui Bi; Xiaohua Wu; Guihao Ke
Journal:  J Cancer       Date:  2020-10-23       Impact factor: 4.207

10.  Prognosis of stage III cervical cancer: a two-way outcome study.

Authors:  Huihui Zhou; Qi Li; Chunyan Xu; Hong Liang; Yanan Wang; Yani Duan; Min Song; Yaoxian Wang; Hong Jin; Tong Wang
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.